Laura Semenzato, Jacques Blacher, Emmanuelle Dufour, Antoine Rachas, Mahmoud Zureik, Valérie Olié
{"title":"Temporal trends in permanent pacemaker implantations in France (2018-2024).","authors":"Laura Semenzato, Jacques Blacher, Emmanuelle Dufour, Antoine Rachas, Mahmoud Zureik, Valérie Olié","doi":"10.1016/j.acvd.2026.07.011","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.07.011","url":null,"abstract":"<p><strong>Background: </strong>Changes in pacemaker implantation indications, population ageing, the emergence of leadless pacing systems and atrioventricular block following transcatheter aortic valve implantation may have influenced recent implantation trends.</p><p><strong>Aims: </strong>This nationwide study aimed to describe temporal trends and patient characteristics of permanent pacemaker implantation in France between 2018 and 2024.</p><p><strong>Methods: </strong>All patients newly implanted with a permanent pacemaker between 2018 and 2024 were identified using the French National Health Data System (SNDS). Age- and sex-standardized annual incidence rates were calculated. Patient characteristics, hospitalization settings and device types were analysed, and national pacemaker prevalence was estimated for 2024.</p><p><strong>Results: </strong>In 2024, 492,583 patients were living with a permanent pacemaker in France (standardized prevalence of 645 per 100,000 population). A total of 51,739 incident implantations were identified (61.5% men; mean age 80.1 years), with 6.8% of procedures following TAVI. The median time to pacemaker replacement was 9.0 years (interquartile range 7.7-10.5). The age- and sex-standardized incidence rate slightly declined (83-73 per 100,000) over the study period, driven primarily by a reduction in implantations performed in private healthcare facilities. Although dual-chamber pacemakers remained the most frequently implanted devices, the use of leadless pacemakers within single-chamber systems has steadily increased since 2019 and was more frequent in less socioeconomically deprived populations, even after adjustment for comorbidity burden.</p><p><strong>Conclusions: </strong>A modest decline in incidence of permanent pacemaker implantation was observed in France between 2018 and 2024, with a more pronounced decrease in private healthcare settings. The observed disparities, especially regarding access to leadless pacing systems, suggest potential differences in healthcare access or clinical practice patterns.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Gut microbiota-targeted interventions with probiotics, prebiotics or synbiotics in acute and stable coronary artery disease: A scoping review of human evidence.","authors":"Johan Schwab, Caroline Chong-Nguyen","doi":"10.1016/j.acvd.2026.09.007","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.09.007","url":null,"abstract":"<p><p>Gut microbiota dysbiosis has been implicated in atherogenesis and the systemic inflammatory pathways underlying acute coronary syndromes (ACS). Synbiotics, which combine prebiotic substrates with live probiotic microorganisms, may provide complementary microbiota-modulating effects. However, their role in coronary artery disease (CAD), particularly after ACS, remains unclear. We conducted a scoping review of PubMed, Ovid, Cochrane Library, ScienceDirect, Embase and Web of Science from inception to September 2026. Eligible studies were peer-reviewed human studies evaluating probiotic, prebiotic or synbiotic supplementation in acute and stable CAD. Preclinical studies and studies limited to anthropometric, lipid or glucose outcomes were excluded. Ongoing registered clinical trials were also screened. Among 2085 records, six studies met the inclusion criteria: three randomized controlled trials, one non-randomized controlled intervention study, one before-after study and one cross-sectional study. Importantly, no study enrolled patients with ACS. Randomized trials reported improvements in inflammatory biomarkers, angina symptoms and endothelial function. Two synbiotic interventions reduced circulating lipopolysaccharide and inflammatory cytokines, with improved nitric oxide bioavailability in one study. No study assessed major adverse cardiovascular events, recurrent ACS or mortality as pre-specified endpoints. Screening of ongoing trials identified only one registered randomized trial specifically investigating synbiotic supplementation after ACS. This review identified a specific evidence gap: despite mechanistic and biomarker evidence supporting microbiota modulation in stable CAD, its role after ACS remains largely unstudied. Our group is conducting SYMBIO-ACS, a randomized pilot trial of synbiotic supplementation after ACS (NCT07411287), to generate initial mechanistic and clinical evidence.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jean-Guillaume Dillinger, Manveer Singh, Jacques Monsegu, Gilles Lemesle
{"title":"The fifth universal definition of myocardial infarction (2026): A new revolution for our practice?","authors":"Jean-Guillaume Dillinger, Manveer Singh, Jacques Monsegu, Gilles Lemesle","doi":"10.1016/j.acvd.2026.10.409","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.10.409","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to a letter from Ahmet Güner et al. on the article entitled \"Chronic total occlusion and outcomes after out-of-hospital cardiac arrest with ST-segment elevation myocardial infarction\" by V. Pham et al.","authors":"Vincent Pham, Fabien Picard","doi":"10.1016/j.acvd.2026.09.006","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.09.006","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gauthier Beuque, Jean Baptiste De Freminville, Alexandre Boutigny, Josselin Duchateau, Benoit Lequeux, Atul Pathak, Guillaume Bailly, Romain Boulestreau
{"title":"Bottlenecks in cardiovascular prevention: Can artificial intelligence close the gap?","authors":"Gauthier Beuque, Jean Baptiste De Freminville, Alexandre Boutigny, Josselin Duchateau, Benoit Lequeux, Atul Pathak, Guillaume Bailly, Romain Boulestreau","doi":"10.1016/j.acvd.2026.09.005","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.09.005","url":null,"abstract":"<p><p>Cardiovascular diseases are a leading cause of morbidity and mortality in France, despite current preventive strategies and evidence-based therapies. Artificial intelligence (AI) has emerged as a promising approach to overcoming several of these barriers, with the potential to improve cardiovascular prevention across the entire spectrum of care. Upstream, AI can enhance risk stratification through the integration of clinical, biological, imaging, environmental, behavioural and longitudinal data, thereby moving cardiovascular prevention toward an AI-augmented precision medicine paradigm, in which risk assessments are increasingly individualized. Downstream, AI-enabled clinical decision support systems may improve guideline implementation, reduce therapeutic inertia and support individualized treatment optimization. Generative AI may also strengthen patient education, personalize risk communication, promote healthy behaviours and improve long-term adherence through adaptive coaching and continuous monitoring. However, translating these promises into meaningful improvements in cardiovascular outcomes will require overcoming substantial technological, organizational, regulatory and societal challenges. These challenges include ensuring data quality and information system interoperability, addressing inequalities in access to digital health technologies, improving the acceptability of AI among patients and healthcare professionals through rigorous evaluation and, critically, adapting healthcare systems to absorb, triage and manage the potentially large number of at-risk individuals identified by AI-enabled prevention strategies. By examining these barriers, this review highlights that AI mainly shifts the bottlenecks of prevention downstream, rather than removing them, and outlines the conditions required for AI, beyond intrinsic performance, to improve cardiovascular prevention in routine clinical practice.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149247575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jean-Baptiste Robiaud, Arthur Leroy-Mobeche, Gilles Berrut, Lionel Moulis, Manuela Dalberto, Mélissa Gentreau, Georges Marroun, Florence Leclercq, Hubert Blain
{"title":"Incidence and predictors of urinary tract infections after sodium-glucose cotransporter 2 inhibitor initiation in older adults hospitalized for heart failure.","authors":"Jean-Baptiste Robiaud, Arthur Leroy-Mobeche, Gilles Berrut, Lionel Moulis, Manuela Dalberto, Mélissa Gentreau, Georges Marroun, Florence Leclercq, Hubert Blain","doi":"10.1016/j.acvd.2026.09.004","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.09.004","url":null,"abstract":"<p><strong>Background: </strong>Sodium-glucose cotransporter 2 inhibitors are recommended for heart failure treatment across the spectrum of ejection fraction; however, by promoting glycosuria, they may increase the risk of urinary tract infection, particularly in older adults.</p><p><strong>Aims: </strong>To assess the 6-month incidence of urinary tract infection following sodium-glucose cotransporter 2 inhibitor initiation in older patients hospitalized for heart failure, and to identify associated factors.</p><p><strong>Methods: </strong>This retrospective single-centre study included patients aged≥75 years hospitalized for heart failure in geriatric and cardiology wards, and initiated on a sodium-glucose cotransporter 2 inhibitor between January 2022 and December 2024. The primary outcome was physician-diagnosed antibiotic-treated suspected urinary tract infection within 6 months, investigated using multivariable logistic regression.</p><p><strong>Results: </strong>Of 260 included patients, 147 were hospitalized in the cardiology ward and 113 in the geriatric ward. Physician-diagnosed antibiotic-treated suspected urinary tract infection was recorded in 45 patients, corresponding to 17.3% of the total cohort and 21.0% of patients with an ascertainable outcome; the upper bound under the extreme worst-case assumption was 35.0%. Incidence was higher in the geriatric ward than in the cardiology ward (26.6 vs. 10.2%). After age matching, female sex (odds ratio 3.15, 95% confidence interval 1.22-8.14), history of urinary tract infection (odds ratio 3.05, 95% confidence interval 1.25-7.42), diabetes mellitus (odds ratio 3.17, 95% confidence interval 1.32-7.60) and geriatric ward hospitalization (odds ratio 3.84, 95% confidence interval 1.62-9.07) were associated with increased odds of urinary tract infection, although only history of urinary tract infection remained robust across missing-outcome sensitivity analyses.</p><p><strong>Conclusions: </strong>Suspected urinary tract infection was frequent after sodium-glucose cotransporter 2 inhibitor initiation in hospitalized older adults. History of urinary tract infection was the most robust predictor, supporting individualized risk assessment and monitoring rather than routine prophylaxis.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter in response to the article entitled \"Chronic total occlusion and outcomes after out-of-hospital cardiac arrest with ST-segment elevation myocardial infarction\" by Pham et al.","authors":"Ahmet Güner, Ahmet Yaşar Çizgici","doi":"10.1016/j.acvd.2026.09.003","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.09.003","url":null,"abstract":"","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Martin Wendlassida Nacanabo, Anna Tall-Thiam, André Arthur Taryètba Seghda, Ella Hatoula Lengani, Prisca Lamoudi Thiombiano, Claudine Djième Dah, Mureille Loya-Abouga, Aimé Arsène Yaméogo, Adolphe Benjamin Ouattara-Zingé, Georges Christian Rosario Millogo, Jonas Koudougou Kologo, Yibar Kambiré, Valentin Nobila Yaméogo, André Koudnoaga Samadoulougou, Patrice Zabsonré
{"title":"Rheumatic lesions of the pulmonary valve: A systematic review of the literature.","authors":"Martin Wendlassida Nacanabo, Anna Tall-Thiam, André Arthur Taryètba Seghda, Ella Hatoula Lengani, Prisca Lamoudi Thiombiano, Claudine Djième Dah, Mureille Loya-Abouga, Aimé Arsène Yaméogo, Adolphe Benjamin Ouattara-Zingé, Georges Christian Rosario Millogo, Jonas Koudougou Kologo, Yibar Kambiré, Valentin Nobila Yaméogo, André Koudnoaga Samadoulougou, Patrice Zabsonré","doi":"10.1016/j.acvd.2026.07.010","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.07.010","url":null,"abstract":"<p><strong>Background: </strong>Rheumatic pulmonary valve disease accounts for<1% of cases of rheumatic heart disease. Because of its rarity, this valvular disease is often overlooked and underdiagnosed.</p><p><strong>Aim: </strong>To conduct a systematic review of reported cases of rheumatic pulmonary valve disease worldwide.</p><p><strong>Methods: </strong>Studies reporting confirmed cases of rheumatic pulmonary valve disease, and providing sufficient clinical, diagnostic, therapeutic or follow-up data were included. Duplicate checking, selection, data extraction and quality assessment of the included studies were carried out by two reviewers, independently. The Joanna Briggs Institute critical appraisal tools were used for quality assessment. The process did not result in a meta-analysis because of significant heterogeneity and a lack of data. The review protocol is registered on the Prospective Registry of Systematic Reviews (CRD420261341732).</p><p><strong>Results: </strong>We identified 909 publications across the six databases. Following deduplication and selection, we included a total of 30 studies involving 35 patients, published between 1931 and 2025. Case reports predominated, accounting for 87% of studies (n=26); case series accounted for 13% (n=4). Age ranged from 3 to 83 years (median 29 years). There was a female predominance (n=20; 57%). India accounted for 37% of cases (n=13), followed by the USA with 11% (n=4). Only 46% of patients (n=16) presented with acute rheumatic fever or pre-existing rheumatic heart disease on admission. Dyspnoea was a constant symptom in all patients. Seven patients (20%) presented with atrial fibrillation. A procedure was performed in 74% of cases (n=26): pulmonary valve replacement in 40% (n=14); balloon dilation in 11% (n=4); and intraoperative commissurotomy in 20% (n=7). The clinical outcome was favourable in 74% of the documented cases (n=26).</p><p><strong>Conclusions: </strong>Rheumatic pulmonary valve disease is a rare condition, but is likely to be underdiagnosed and underreported; it most commonly forms part of a quadrivalent valve disease. This review highlights the need for increased clinical and paraclinical vigilance when assessing the pulmonary valve in rheumatic heart disease.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149208180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Niki Procopi, Paul Guedeney, Arnaud Ferrante, Michel Zeitouni, Mathieu Kerneis, Olivier Barthelemy, Claude Le Feuvre, Johanne Silvain, Emmanuel Berman, Ghilas Rahoual, Victorien Monguillon, David Sulman, Marie Dupuy, Louis Giovachini, Pierre Charleux, Guillaume Coutance, Shaida Varnous, Pascal Leprince, Guillaume Lebreton, Gilles Montalescot, Gérard Helft
{"title":"Incidence and determinants of non-radial vascular approach for coronary angiography in heart transplant recipients.","authors":"Niki Procopi, Paul Guedeney, Arnaud Ferrante, Michel Zeitouni, Mathieu Kerneis, Olivier Barthelemy, Claude Le Feuvre, Johanne Silvain, Emmanuel Berman, Ghilas Rahoual, Victorien Monguillon, David Sulman, Marie Dupuy, Louis Giovachini, Pierre Charleux, Guillaume Coutance, Shaida Varnous, Pascal Leprince, Guillaume Lebreton, Gilles Montalescot, Gérard Helft","doi":"10.1016/j.acvd.2026.07.009","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.07.009","url":null,"abstract":"<p><strong>Background: </strong>Heart transplantation (HT) recipients undergo repeated coronary angiographies to screen for coronary allograft vasculopathy, which increases exposure to non-radial vascular access and potential related complications.</p><p><strong>Aims: </strong>To describe the incidence and determinants of non-radial vascular approach among HT recipients in a large HT centre.</p><p><strong>Methods: </strong>Consecutive HT recipients undergoing coronary angiography between October 2020 and March 2024 in the largest European HT centre were included, and all their previous coronary angiographies performed after HT were retrospectively reviewed. Determinants of non-radial vascular approach were assessed using multivariable logistic regression analyses, which included the individual mean number of coronary angiographies per year after HT to account for disparities in follow-up.</p><p><strong>Results: </strong>A total of 429 patients (21.4% female, median [interquartile range] age at HT 50 [38-58] years) underwent a total of 1927 procedures, with a median number of 3 (1-7) coronary angiographies per patient performed over a median duration of 6.7 (1.3-12.9) years. The cumulative rate of non-radial vascular approach at 10 years was 35.5% (95% confidence interval: 29.9-41.1%). Independent determinants of non-radial vascular approach were HT for ischaemic heart disease (adjusted odds ratio [aOR]: 2.78, 95% confidence interval [95% CI]: 1.69-4.54), multiple HT (aOR: 5.71, 95% CI: 1.42-23.01), female sex (aOR: 2.22, 95% CI: 1.18-4.16) and chronic dialysis after HT (aOR: 3.19, 95% CI: 1.09-9.28), but the number of procedures was not. Severe vascular complications were rare and not significantly different between vascular accesses.</p><p><strong>Conclusions: </strong>In this high-volume centre, non-radial vascular approach was used in approximately one third of HT recipients during their follow-up, with multiple reasons, albeit not including the overall number of procedures performed.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Omar Obaidat, Laith Alhuneafat, Samarth Goyal, Ala Abdallah, Hamza Hawamleh, Ahmad Abdouh, Ahmad Jabri, Wissam Khalife, Valmiki Maharaj
{"title":"Use of contemporary cardiometabolic therapies in cardiac amyloidosis treated with tafamidis: A real-world propensity-matched analysis.","authors":"Omar Obaidat, Laith Alhuneafat, Samarth Goyal, Ala Abdallah, Hamza Hawamleh, Ahmad Abdouh, Ahmad Jabri, Wissam Khalife, Valmiki Maharaj","doi":"10.1016/j.acvd.2026.06.076","DOIUrl":"https://doi.org/10.1016/j.acvd.2026.06.076","url":null,"abstract":"<p><strong>Background: </strong>Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart failure, and is associated with poor prognosis. Although tafamidis stabilizes transthyretin and improves survival, the role of adjunctive heart failure therapies in this population remains uncertain.</p><p><strong>Aims: </strong>To evaluate the association between contemporary pharmacotherapies, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists (MRAs), sacubitril/valsartan, glucagon-like peptide-1 (GLP-1) receptor agonists and beta-blockers, and clinical outcomes among tafamidis-treated patients with ATTR-CM.</p><p><strong>Methods: </strong>We conducted a multicentre retrospective cohort study using the TriNetX Research Network. Adult patients with ATTR-CM who were prescribed tafamidis between 2019 and 2025 were included. Medication exposure was defined within 90 days of tafamidis initiation. Propensity score matching was applied for each drug class comparison. Outcomes included all-cause mortality, cardiovascular events, hospitalizations, emergency department visits and renal complications assessed at 1 and 5 years.</p><p><strong>Results: </strong>Among 5683 patients with tafamidis-treated ATTR-CM, the mean age was 78.1 years, and 81% were male. SGLT2 inhibitor use was associated with lower all-cause mortality at 1 and 5 years, with hazard ratios of 0.56 and 0.62, respectively, as well as lower rates of heart failure hospitalization and major adverse cardiovascular events at 5 years. MRAs were not associated with a mortality benefit, but were associated with higher risks of atrial fibrillation, acute kidney injury and emergency department visits. Sacubitril/valsartan was associated with lower rates of major adverse cardiovascular events and hospitalization at 5 years. GLP-1 receptor agonist use showed favourable trends in hospitalization-related outcomes, but the analysis was limited by the small sample size, and should be considered exploratory. Beta-blockers were associated with higher rates of adverse cardiovascular events and emergency department visits, without evidence of survival benefit. These adverse signals should be interpreted as hypothesis generating.</p><p><strong>Conclusions: </strong>In tafamidis-treated patients with ATTR-CM, SGLT2 inhibitor use was associated with lower mortality and improved cardiovascular outcomes. In contrast, MRAs and beta-blockers were not associated with survival benefit, and showed unfavourable associations with morbidity and healthcare utilization. Sacubitril/valsartan and GLP-1 receptor agonists appeared safe, and showed favourable trends in selected outcomes. These findings require prospective confirmation before influencing clinical practice.</p>","PeriodicalId":55472,"journal":{"name":"Archives of Cardiovascular Diseases","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149396282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}